Skip to content
AnalystLens

Merck 8-K Report, Financial Results (Feb 1, 2024)

Reports
Earnings & Results·Financial Events·Exhibits & Filings
Filing Date
Filed February 1, 2024
Period End
January 29, 2024
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed February 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Merck (MRK) reported fourth-quarter and full-year 2023 results on February 1, 2024.

Full-year 2023 sales were $60.1 billiona, up 1% reported and 4% excluding foreign exchange, with Keytruda ($25.0 billion, up 19%) and Gardasil/Gardasil 9 ($8.9 billion, up 29%) driving growth, offset by a 75% decline in COVID-19 antiviral LAGEVRIO to $1.4 billion. Profitability was sharply lower on a GAAP basis: full-year GAAP EPS fell to $0.14 from $5.71, largely due to $6.21 per share of business development charges (including a $5.5 billion Daiichi Sankyo collaboration charge in Q4 and $11.4 billion across the Prometheus and Imago acquisitions). Non-GAAP EPS was $1.51 versus $7.48 in 2022.

Excluding these charges, the underlying business showed improved gross margin (non-GAAP 76.9%, up from 74.4%) and operational strength. The company also disclosed a new 2024 Restructuring Program, approved January 29, 2024, with cumulative pretax costs of about $4.0 billionb through the end of 2031. Roughly 60% is non-cash accelerated depreciation tied to facility closures or divestitures, and the rest is largely cash facility shutdown costs.

The program targets Human Health manufacturing as the pipeline shifts to new modalities and Animal Health manufacturing efficiency. Only $190 millionc was recorded in 2023, so the bulk of the charge will fall in future periods.

For 2024, Merck guided to sales of $62.7 to $64.2 billiond and non-GAAP EPS of $8.44 to $8.59, which includes roughly $0.26 per share of one-time Harpoon acquisition charges and about $0.25 per share of foreign exchange headwind. Investors will focus on whether Keytruda and Gardasil growth can offset the expected LAGEVRIO decline, the pace of R&D spending tied to recent acquisitions, and the cash cost of the new restructuring program.

Key Highlights

  1. Full-year 2023 sales of $60.1B, up 1% reported and 4% ex-FX; ex-LAGEVRIO growth was 9% reported and 12% ex-FX.
  2. Keytruda grew 19% to $25.0B and Gardasil/Gardasil 9 grew 29% to $8.9B, anchoring the oncology and vaccine franchises.
  3. GAAP EPS fell to $0.14 from $5.71 and non-GAAP EPS to $1.51 from $7.48, driven by $6.21 per share of business development charges.
  4. Non-GAAP gross margin improved to 76.9% from 74.4%, helped by lower LAGEVRIO sales and lower manufacturing costs.
  5. New 2024 Restructuring Program targets about $4.0B in cumulative pretax costs through 2031, with roughly 60% non-cash.
  6. 2024 guidance: sales of $62.7B to $64.2B and non-GAAP EPS of $8.44 to $8.59, including about $0.26 per share of Harpoon-related charges.
  7. Q4 2023 GAAP loss per share of $0.48 reflected a $1.69 per share charge for the Daiichi Sankyo collaboration; non-GAAP EPS was just $0.03.

Frequently Asked Questions

  1. Why did Merck's GAAP earnings fall so sharply in 2023?

    The decline was mainly due to business development charges totaling $6.21 per share, including a $5.5 billion R&D charge for the Daiichi Sankyo collaboration and $11.4 billion in charges for the Prometheus and Imago acquisitions. A $572.5 million Zetia antitrust settlement, unfavorable foreign exchange, and a higher effective tax rate of 80.0% also contributed.

  2. What is the 2024 Restructuring Program and what will it cost?

    Approved January 29, 2024, the program aims to optimize Human Health manufacturing as the pipeline shifts to new modalities and improve Animal Health manufacturing efficiency. Cumulative pretax costs are estimated at about $4.0 billion through 2031, with roughly 60% non-cash accelerated depreciation and the remainder mainly cash facility shutdown costs. Only $190 million was recorded in 2023.

  3. How strong is the underlying business excluding one-time charges?

    Excluding LAGEVRIO and currency effects, full-year sales grew 12%. Keytruda and Gardasil drove most of the growth, and non-GAAP gross margin rose to 76.9% from 74.4%. Non-GAAP EPS was depressed by the business development charges rather than by weakness in core operations.

  4. What does 2024 guidance imply for investors?

    Merck expects sales of $62.7 to $64.2 billion, implying modest growth from 2023's $60.1 billion, and non-GAAP EPS of $8.44 to $8.59. Guidance includes about $0.26 per share for the Harpoon acquisition and a roughly $0.25 per share foreign exchange headwind, and it assumes no additional significant business development deals.

  5. What risks does the LAGEVRIO decline pose?

    LAGEVRIO sales fell 75% to $1.4 billion in 2023 as COVID-19 demand receded. Because the product carried a low gross margin, its decline actually helped margins in 2023, but it removes a revenue source that Merck must replace with growth in Keytruda, Gardasil, and its newer products.